DALLAS, April 26, 2021 / PRNewswire / – Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“AI”) platform to transform the discovery and development of oncology drugs, announced a manuscript detailing the efficacy profile of LP described -184 in a variety of non-small cell lung cancer models was published in Oncotarget. The manuscript is entitled ‘The acylfulveen alkylating agent, LP-184, maintains nanomolar potency in non-small cell lung cancer that otherwise carries treatment-resistant mutations’. LP-184 is being developed by Lantern for the potential treatment of non-small cell lung cancer (NSCLC) in addition to several other targeted indications in solid tumors, including pancreatic and CNS cancers.
The unmet clinical need where LP-184-based therapy could potentially be of value is for those non-small cell lung cancer patients who are not eligible for targeted therapy options or who have developed resistance to other forms of therapy. Existing targeted therapies, such as EGFR or ALK inhibitors, only work in specific, genetically defined patient subgroups. There is a significant proportion of lung cancers – 30 to 40 percent – who do not have these intended changes, or who have developed resistance to current standard of care treatments, often leaving lung cancer patients without additional therapeutic options. According to Panna Sharma, CEO of Lantern Pharma, “More people die of lung cancer each year than any other cancer, and significant improvements have been made in the era of targeted and combination therapies; however, many lung cancers are developing rapidly and forming resistance to both targeted and targeted agents as combinations of chemotherapy, and there is a great clinical need for new options and possibly further prolongation of patients’ lives. “Mr. Sharma continued:” With this additional indication for our DNA damaging agent, LP-184, we continue to we invest in the development of therapeutic options to increase the personalization of therapy for lung cancer patients. “
This publication in Oncotarget highlights the nanomolar in vitro potency of LP-184 in primary and metastatic NSCLC models. It also shows that LP-184 is generally more potent in vitro than commonly prescribed platinum and taxane-based chemotherapeutics. Based on the study conducted, the activity profile of LP-184 is not affected by the presence of mutations in major oncogenes such as KRAS or KEAP1 and tumor suppressors such as TP53 and STK11, which otherwise underlie resistance to other drugs. LP-184 is believed to be a promising drug candidate that may address the treatment of KEAP1 mutant NSCLC, because the mutations up-regulate PTGR1 expression, and increased PTGR1 in turn renders tumor cells increasingly sensitive to LP-184.
In addition, LP-184 showed inhibition of tumor growth in a murine xenograft model of KRAS / KEAP1 mutant lung cancer. Concurrent KRAS and KEAP1 mutations occur in about 17 percent of lung adenocarcinoma cases and are believed to represent an aggressive lung cancer believed to be “incurable.” Lantern Pharma has developed a genomic signature believed to predict response in tumors that will respond to LP-184. This correlation and localization of clinical need were supported by further TCGA analysis of 517 lung adenocarcinoma patients, of which 35% showed increased PTGR1 and 40% of those further statistically significant co-occurrence of KEAP1 mutations. Given an overlap between LP-184 specific response biomarkers and NSCLC-related genomic groups, we believe that the clinical data analyzes reveal patient subgroups with different molecular backgrounds likely to respond to LP-184 and benefit from this drug candidate.
According to Mr. Sharma, “Using our data-driven approach, we have shown that we can not only find unique biomarkers related to drug response and mechanism, but also quickly discover clinically meaningful subgroups of patients who can benefit of our portfolio of therapies. ”Mr. Sharma continued,“ By understanding the genomic and biomarker characteristics that drive the activity of a substance in different cancer subtypes, we can rapidly develop new meaningful indications that have the potential to provide life-altering therapy options for cancer patients – and we can do this faster and with better insights as a result of our RADR® platform. We will continue to invest in increasing the data, scope and functionality of the AI platform and expect it to play a broader role in cancer therapy development.
Lantern continues to validate LP-184 sensitivity in advanced lung tumor models, both as monotherapy and in combination with drugs prioritized in Lantern’s RADR® models, to increase the potential future benefit for patients with tumors that may or may not be “incurable”. have been or have become. -respons to existing approved therapies.
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company that leverages its proprietary RADR® AI platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomic-targeted therapies. Lantern is currently developing four drug candidates and an ADC program for seven revealed tumor targets, including two Phase 2 programs. By targeting drugs to patients whose genomic profile indicates they are most likely to benefit from the drug, Lantern’s approach represents the potential to achieve the best results. More information can be found at: www.lanternpharma.com and Twitter @lanternpharma.
LP-184 is currently in multiple studies in collaboration with leading cancer research institutions. With the help of our RADR® AI platform, the mechanism of action of LP-184 has been well characterized by numerous in silico and in vivo studies and described in published peer-reviewed articles. With observed nanomolar potency and blood brain barrier permeability, LP-184 is an alkylating agent that works by causing DNA damage in tumor cells. As demonstrated by CRISPR gene editing techniques, LP-184 activity is dependent on the expression of Prostaglandin Reductase 1 (“PTGR1”), which converts LP-184 to its bioactive form through the oxidoreductase activity of PTGR1.
Marek Ciszewski, JD
Director, Investor Relations
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include statements regarding: future events or our future financial performance; the potential benefits of our RADR® platform in identifying drug candidates and patient populations likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and the antibody conjugate development program (ADC); estimates regarding the timing of development of our drug candidates and ADC’s development program; our research and development efforts of our in-house drug discovery programs and using our RADR® platform to streamline the drug development process; our intention to use artificial intelligence, machine learning and genomic data to streamline and transform the pace, risks and costs of oncology drug discovery and development and to identify patient populations likely to respond to a drug candidate; estimates of potential markets and potential market size; sales estimates for our drug candidates and our plans to discover and develop drug candidates and maximize their commercial potential by promoting such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, but not limited to, statements using words such as’ anticipate ‘,’ believe ‘,’ consider ‘,’ could ‘,’ estimate ‘,’ expect ‘,’ intend be ‘, search,’ ‘could’ ‘,’ could ‘,’ plan ‘,’ potential ‘,’ predict ‘,’ project ‘,’ aim ‘,’ aim ‘,’ should ‘,’ want ‘,’ or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that none of our product candidates have received FDA marketing approval and we may not be able to successfully initiate, conduct or complete clinical trials for our product candidates or obtain marketing approval; (iii) the risk that no drug based on our proprietary RADR AI platform has received marketing approval from the FDA or is otherwise included in a commercial product, and (iv) those other factors set out in the Risk Factors section of our annual report on form 10-K for the past year December 31, 2020, filed with the Securities and Exchange Commission on March 10, 2021. You can access our annual report on Form 10-K for the past year December 31, 2020 under the Investor SEC filings tab of our website www.lanternpharma.com or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we cannot make any assurances that our forward-looking statements will prove to be accurate, or that other results or events projected or contemplated by our forward-looking statements will also materialize, and we caution investors not to do so . placing undue reliance on these statements. All forward-looking statements in this press release represent our opinion as of the date hereof, and, unless otherwise required by law, we disclaim any obligation to update forward-looking statements to reflect actual results or changes in our expectations . .
View original content to download multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-publication-detailing-preclinical-results-of-drug-candidate-lp-184-in-a-spectrum-of-drug-resistant- lung-cancer-in-the-journal-oncotarget-301276671.html
SOURCE Lantern Pharma